Skip to content
WorldBrand.AI

Jiangsu Kanion Pharmaceutical Co., Ltd. controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile1 entries

  1. 2023

    R&D expense recognition violation: annual report overstated by 10.5 million yuan, company warned

    In May 2023, the Jiangsu Securities Regulatory Bureau determined that Kanion Pharmaceutical's recognition of R&D expenses in 2019 did not comply with accounting standards and overstated expenses by 10.5 million yuan, issuing warning letters to the company and its then chief financial officer and board secretary.

    Source